Claims

1. A compound of formula I,



I

wherein

Q, Y are independently of one another CH or N,

R^1 is Hal or linear or branched alkyl having 1-10 C atoms which is unsubstituted or mono-, di- or trisubstituted by R^4 and in which 1-4 C atoms may be replaced, independently of one another, by O, S, SO, SO_2, NH, NCH_3, –OCO–, –NHCONH–, –NHCO–, $–NR^5SO_2R^6–$, –COO–, –CONH–, $–NCH_3CO–$, $–CONCH_3–$, –C≡C– groups and/or –CH=CH– groups, and/or 1-10 H atoms may be replaced by F and/or Cl, or mono- or bicyclic cyclic alkyl having 3-7 C atoms which is unsubstituted or mono-, di- or trisubstituted by R^4 and in which 1-4 C atoms may be replaced, independently of one another, by O, S, SO, SO_2, NH, NCH_3, –OCO–, –NHCONH–, –NHCO–, $–NR^5SO_2R^6–$, –COO–, –CONH–, $–NCH_3CO–$, $–CONCH_3–$, –C≡C– groups and/or by –CH=CH– groups and/or1-10 H atoms may be replaced by F and/or Cl, or mono- or bicyclic heteroaryl, heterocyclyl, aryl or cyclic alkylaryl, containing 3 to 14 carbon atoms and 0-4 heteroatoms, independently selected from the group consisting of N, O and S, which is unsubstituted or mono-, di- or trisubstituted by R^4,

R^2 is linear or branched alkyl having 1-10 C atoms which is unsubstituted or mono-, di- or trisubstituted by R^4 and in which 1-4 C atoms may be replaced, independently of one another, by O, S, SO, SO_2, NH, NCH_3, –OCO–, –NHCONH–, –NHCO–, $–NR^5SO_2R^6–$, –

COO–, –CONH–, –NCH_3CO–, –$CONCH_3$–, –C≡C– groups and/or –CH=CH– groups, and/or1-10 H atoms may be replaced by F and/or Cl, or cyclic alkyl having 3-7 C atoms which is unsubstituted or mono-, di- or trisubstituted by R^4 and in which 1-4 C atoms may be replaced, independently of one another, by O, S, SO, SO_2, NH, NCH_3, –OCO–, –NHCONH–, –NHCO–, –$NR^5SO_2R^6$–, –COO–, –CONH–, –NCH_3CO–, –$CONCH_3$–, –C≡C– groups and/or by –CH=CH– groups and/or1-11 H atoms may be replaced by F and/or Cl, or mono- or bicyclic heteroaryl, heterocyclyl, aryl or cyclic alkylaryl, containing 3 to 14 carbon atoms and 0-4 heteroatoms, independently selected from the group consisting of N, O and S, which is unsubstituted or mono-, di- or trisubstituted by R^4,

R^3 is linear or branched alkyl or O-alkyl having 1-6 C atoms or cyclic alkyl having 3-6 C atoms, which is unsubstituted or mono-, di- or trisubstituted by H, =S, =NH, =O, OH, cyclic alkyl having 3-6 C atoms, COOH, Hal, NH_2, SO_2CH_3, SO_2NH_2, CN, $CONH_2$, $NHCOCH_3$, $NHCONH_2$ or NO_2,

R^4 is H, R^5, =S, =NR^5, =O, OH, COOH, Hal, NH_2, SO_2CH_3, SO_2NH_2, CN, $CONH_2$, $NHCOCH_3$, $NHCONH_2$, NO_2, or linear or branched alkyl having 1-10 C atoms which is unsubstituted or mono-, di- or trisubstituted by R^5 and in which 1-4 C atoms may be replaced, independently of one another, by O, S, SO, SO_2, NH, NCH_3, –OCO–, –NHCONH–, –NHCO–, –$NR^5SO_2R^6$–, –COO–, –CONH–, –NCH_3CO–, –$CONCH_3$–, –C≡C– groups and/or –CH=CH– groups, and/or1-10 H atoms may be replaced by F and/or Cl, or mono- or bicyclic cyclic alkyl having 3-7 C atoms which is unsubstituted or mono-, di- or trisubstituted by R^5 and in which 1-4 C atoms may be replaced, independently of one another, by O, S, SO, SO_2, NH, NCH_3, –OCO–, –NHCONH–, –NHCO–, –$NRSO_2R^4$–, –COO–, –CONH–, –NCH_3CO–, –$CONCH_3$–, –C≡C– groups and/or by –CH=CH– groups and/or1-10 H atoms may be replaced by F and/or Cl, or mono- or bicyclic heteroaryl, heterocyclyl, aryl or cyclic alkylaryl, containing 3 to 14 carbon atoms and 0-4 heteroatoms, independently selected from the group consisting of N, O and S, which is unsubstituted or mono-, di- or trisubstituted by R^5,

R^5, R^6 are independently of one another H, =S, =NH, =O, OH, COOH, Hal, NH_2, SO_2CH_3, SO_2NH_2, CN, $CONH_2$, $NHCOCH_3$, $NHCONH_2$, NO_2 or linear or branched alkyl having 1-10 C atoms in which 1-4 C atoms may be replaced, independently of one another, by O, S, SO, SO_2, NH, NCH_3, –OCO–, –NHCONH–, –NHCO–,–COO–, –CONH–, –NCH_3CO–, –$CONCH_3$–, –C≡C– groups and/or –CH=CH– groups, and/or 1-10 H atoms may be replaced by F and/or Cl,

Hal is F, C, Br, or I,

or a physiologically acceptable salt, derivative, solvate, prodrug or stereoisomer thereof.

2. The compound according to claim 1, wherein

R^1 is linear or branched alkyl having 1-10 C atoms which is unsubstituted or mono-, di- or trisubstituted by R^4 and in which 1-4 C atoms may be replaced, independently of one another, by O, S, SO, SO_2, NH, NCH_3, –OCO–, –NHCONH–, –NHCO–, –$NR^5SO_2R^6$–, –COO–, –CONH–, –NCH_3CO–, –$CONCH_3$–, –C≡C– groups and/or –CH=CH– groups, and/or 1-10 H atoms may be replaced by F and/or Cl, or one of the following structures:



which is unsubstituted or mono-, di- or trisubstituted with R^4.

3. The compound according to claim 1, wherein

Q is CH or N, and

Y is CH.

4. The compound according to claim 1, wherein R^2 is one of the following structures:



which is unsubstituted or mono-, di- or trisubstituted with R^5.

5. The compound according to claim 1, wherein
R^3 one of the following structures



6. The compound according to claim 1, wherein
R^3 is OMe.

7. A compound selected from the group consisting of:

No.	IUPAC-Name
1	N-[8-methoxy-5-(oxan-4-yl)quinoxalin-2-yl]-2-oxa-7-azaspiro[4.4]nonane-7-carboxamide
2	4-hydroxy-N-[8-methoxy-5-(pyridin-4-yl)quinoxalin-2-yl]-4-methylpiperidine-1-carboxamide
3	3-hydroxy-N-[8-methoxy-5-(oxan-4-yl)quinoxalin-2-yl]-3-methylpyrrolidine-1-carboxamide
4	N-[8-methoxy-5-(oxan-4-yl)quinoxalin-2-yl]-2-methyl-1,3-oxazole-4-carboxamide
5	4-(hydroxymethyl)-N-[8-methoxy-5-(oxan-4-yl)quinoxalin-2-yl]-4-methylpiperidine-1-carboxamide
6	N-[8-methoxy-5-(oxan-4-yl)quinoxalin-2-yl]-2,2-dioxo-2lambda6-thia-6-azaspiro[3.3]heptane-6-carboxamide
7	6-methoxy-N-[8-methoxy-5-(oxan-4-yl)quinoxalin-2-yl]pyridazine-3-carboxamide
8	N-[8-methoxy-5-(oxan-4-yl)quinoxalin-2-yl]-1-(2-methoxyethyl)-1H-pyrazole-4-carboxamide
9	4-hydroxy-N-(8-methoxy-5-phenylquinoxalin-2-yl)-4-(prop-2-yn-1-yl)piperidine-1-carboxamide

10	3-hydroxy-N-(8-methoxy-5-phenylquinoxalin-2-yl)-3-methylpyrrolidine-1-carboxamide
11	4-(hydroxymethyl)-N-(8-methoxy-5-phenylquinoxalin-2-yl)-4-methylpiperidine-1-carboxamide
12	N-(8-methoxy-5-phenylquinoxalin-2-yl)-8-oxa-2-azaspiro[4.5]decane-2-carboxamide
13	N-(8-methoxy-5-phenylquinoxalin-2-yl)-2-oxa-7-azaspiro[4.4]nonane-7-carboxamide
14	N-(8-methoxy-5-phenylquinoxalin-2-yl)-2,2-dioxo-2lambda6-thia-6-azaspiro[3.3]heptane-6-carboxamide
15	4-Hydroxy-4-methyl-piperidine-1-carboxylic acid (5-methoxy-8-phenyl-pyrido[3,4-b]pyrazin-3-yl)-amide
16	3-Hydroxy-3-methyl-pyrrolidine-1-carboxylic acid (5-methoxy-8-phenyl-pyrido[3,4-b]pyrazin-3-yl)-amide
17	4-Hydroxymethyl-4-methyl-piperidine-1-carboxylic acid (5-methoxy-8-phenyl-pyrido[3,4-b]pyrazin-3-yl)-amide
18	N-[8-methoxy-5-(oxan-4-yl)quinoxalin-2-yl]-8-oxa-2-azaspiro[4.5]decane-2-carboxamide
19	N-[8-methoxy-5-(oxan-4-yl)quinoxalin-2-yl]acetamide
20	2,2,2-trifluoro-N-[8-methoxy-5-(oxan-4-yl)quinoxalin-2-yl]acetamide
21	4-Dimethylaminomethyl-N-(5-methoxy-8-phenyl-pyrido[3,4-b]pyrazin-3-yl)-benzamide
22	4-Hydroxy-4-prop-2-ynyl-piperidine-1-carboxylic acid (5-methoxy-8-phenyl-pyrido[3,4-b]pyrazin-3-yl)-amide
23	4-Methoxymethyl-N-(5-methoxy-8-phenyl-pyrido[3,4-b]pyrazin-3-yl)-benzamide

24	1-(2-Methoxy-ethyl)-1H-pyrazole-4-carboxylic acid (5-methoxy-8-phenyl-pyrido[3,4-b]pyrazin-3-yl)-amide
25	6-hydroxy-N-[8-methoxy-5-(oxan-4-yl)quinoxalin-2-yl]pyridazine-4-carboxamide
26	8-methoxy-5-(oxan-4-yl)quinoxalin-2-amine
27	(3S)-3-hydroxy-N-[8-methoxy-5-(oxan-4-yl)quinoxalin-2-yl]-3-methylpyrrolidine-1-carboxamide
28	(3R)-3-hydroxy-N-[8-methoxy-5-(oxan-4-yl)quinoxalin-2-yl]-3-methylpyrrolidine-1-carboxamide
29	4-hydroxy-N-[8-methoxy-5-(2-methylphenyl)quinoxalin-2-yl]-4-methylpiperidine-1-carboxamide
30	N-(8-methoxy-5-phenylquinoxalin-2-yl)-1-(2-methoxyethyl)-1H-pyrazole-4-carboxamide
31	N-(8-methoxy-5-phenylquinoxalin-2-yl)-2-methyl-1,3-oxazole-4-carboxamide
32	N-(8-methoxy-5-phenylquinoxalin-2-yl)-1-methyl-1H-pyrazole-4-carboxamide
33	N-(8-methoxy-5-phenylquinoxalin-2-yl)cyclopropanecarboxamide
34	N-(8-methoxy-5-phenylquinoxalin-2-yl)-1-methyl-1H-pyrazole-5-carboxamide
35	N-(8-methoxy-5-phenylquinoxalin-2-yl)-1,3-thiazole-5-carboxamide

36	N-(8-methoxy-5-phenylquinoxalin-2-yl)-2-methyl-1,3-thiazole-5-carboxamide
37	N-(8-methoxy-5-phenylquinoxalin-2-yl)-4H-1,2,4-triazole-3-carboxamide
38	N-[5-(4-fluorophenyl)-8-methoxyquinoxalin-2-yl]-4-hydroxy-4-methylpiperidine-1-carboxamide
39	4-Hydroxy-4-methyl-piperidine-1-carboxylic acid [5-methoxy-8-(tetrahydro-pyran-4-yl)-pyrido[3,4-b]pyrazin-3-yl]-amide
40	N-[8-methoxy-5-(oxan-4-yl)quinoxalin-2-yl]cyclopropanecarboxamide
41	4-Hydroxy-4-methyl-piperidine-1-carboxylic acid [8-methoxy-5-(6-methyl-pyridazin-3-yl)-quinoxalin-2-yl]-amide
42	1-(2-Methoxy-ethyl)-1H-pyrazole-4-carboxylic acid [8-methoxy-5-(6-methyl-pyridazin-3-yl)-quinoxalin-2-yl]-amide
43	1-(2-Methoxy-ethyl)-1H-pyrazole-4-carboxylic acid (8-methoxy-5-pyridin-4-yl-quinoxalin-2-yl)-amide
44	1-(2-Methoxy-ethyl)-1H-pyrazole-4-carboxylic acid [5-methoxy-8-(tetrahydro-pyran-4-yl)-pyrido[3,4-b]pyrazin-3-yl]-amide
45	Isoxazole-4-carboxylic acid (5-methoxy-8-phenyl-pyrido[3,4-b]pyrazin-3-yl)-amide
46	4-Hydroxymethyl-4-methyl-piperidine-1-carboxylic acid [8-methoxy-5-(tetrahydro-pyran-4-yl)-quinoxalin-2-yl]-amide

47	3-Hydroxy-3-methyl-pyrrolidine-1-carboxylic acid [5-methoxy-8-(tetrahydro-pyran-4-yl)-pyrido[3,4-b]pyrazin-3-yl]-amide
48	4-Hydroxy-4-methyl-piperidine-1-carboxylic acid [5-(2-fluoro-phenyl)-8-methoxy-quinoxalin-2-yl]-amide
49	4-Hydroxy-4-methyl-piperidine-1-carboxylic acid [5-(4-fluoro-phenyl)-8-methoxy-quinoxalin-2-yl]-amide
50	4-Hydroxy-4-methyl-piperidine-1-carboxylic acid [5-(3-fluoro-phenyl)-8-methoxy-quinoxalin-2-yl]-amide
51	4-Hydroxy-4-methyl-piperidine-1-carboxylic acid [8-methoxy-5-(2-oxa-7-aza-spiro[4.4]non-7-yl)-quinoxalin-2-yl]-amide
52	4-Hydroxy-4-methyl-piperidine-1-carboxylic acid (8-methoxy-5-pyridin-3-yl-quinoxalin-2-yl)-amide
53	4-Hydroxy-4-methyl-piperidine-1-carboxylic acid (5-azepan-1-yl-8-methoxy-quinoxalin-2-yl)-amide
54	4-Hydroxy-4-methyl-piperidine-1-carboxylic acid (8-methoxy-5-phenyl-pyrido[3,4-b]pyrazin-2-yl)-amide
55	Isoxazole-4-carboxylic acid [5-methoxy-8-(tetrahydro-pyran-4-yl)-pyrido[3,4-b]pyrazin-3-yl]-amide
56	1-Methyl-1H-pyrazole-4-carboxylic acid [8-methoxy-5-(tetrahydro-pyran-4-yl)-quinoxalin-2-yl]-amide

57	5-Methyl-isoxazole-4-carboxylic acid [8-methoxy-5-(tetrahydro-pyran-4-yl)-quinoxalin-2-yl]-amide
58	5-Cyclopropyl-isoxazole-4-carboxylic acid [8-methoxy-5-(tetrahydro-pyran-4-yl)-quinoxalin-2-yl]-amide
59	1-(2-Methoxy-ethyl)-1H-[1,2,3]triazole-4-carboxylic acid [8-methoxy-5-(tetrahydro-pyran-4-yl)-quinoxalin-2-yl]-amide
60	1-Methyl-1H-[1,2,3]triazole-4-carboxylic acid [8-methoxy-5-(tetrahydro-pyran-4-yl)-quinoxalin-2-yl]-amide
61	1-Cyano-cyclopropanecarboxylic acid [8-methoxy-5-(tetrahydro-pyran-4-yl)-quinoxalin-2-yl]-amide
62	Cyclopropanesulfonic acid [8-methoxy-5-(tetrahydro-pyran-4-yl)-quinoxalin-2-yl]-amide
63	[8-Methoxy-5-(tetrahydro-pyran-4-yl)-quinoxalin-2-yl]-carbamic acid isopropyl ester
64	2-Methyl-2H-pyrazole-3-carboxylic acid [8-methoxy-5-(tetrahydro-pyran-4-yl)-quinoxalin-2-yl]-amide
65	Thiazole-5-carboxylic acid [8-methoxy-5-(tetrahydro-pyran-4-yl)-quinoxalin-2-yl]-amide
66	2-Methyl-thiazole-5-carboxylic acid [8-methoxy-5-(tetrahydro-pyran-4-yl)-quinoxalin-2-yl]-amide
67	1H-[1,2,4]Triazole-3-carboxylic acid [8-methoxy-5-(tetrahydro-pyran-4-yl)-quinoxalin-2-yl]-amide

68	2,3-Dimethyl-3H-imidazole-4-sulfonic acid [8-methoxy-5-(tetrahydro-pyran-4-yl)-quinoxalin-2-yl]-amide
69	Imidazo[1,2-a]pyrazine-2-carboxylic acid [8-methoxy-5-(tetrahydro-pyran-4-yl)-quinoxalin-2-yl]-amide
70	Azetidine-3-carboxylic acid [8-methoxy-5-(tetrahydro-pyran-4-yl)-quinoxalin-2-yl]-amide
71	Azetidine-3-carboxylic acid (8-methoxy-5-phenyl-quinoxalin-2-yl)-amide
72	Imidazo[1,2-a]pyrazine-2-carboxylic acid (8-methoxy-5-phenyl-quinoxalin-2-yl)-amide
73	2,3-Dimethyl-3H-imidazole-4-sulfonic acid (8-methoxy-5-phenyl-quinoxalin-2-yl)-amide
74	(8-Methoxy-5-phenyl-quinoxalin-2-yl)-carbamic acid isopropyl ester
75	Cyclopropanesulfonic acid (8-methoxy-5-phenyl-quinoxalin-2-yl)-amide
76	1-Cyano-cyclopropanecarboxylic acid (8-methoxy-5-phenyl-quinoxalin-2-yl)-amide
77	1-Methyl-1H-[1,2,3]triazole-4-carboxylic acid (8-methoxy-5-phenyl-quinoxalin-2-yl)-amide
78	1-(2-Methoxy-ethyl)-1H-[1,2,3]triazole-4-carboxylic acid (8-methoxy-5-phenyl-quinoxalin-2-yl)-amide

79	5-Cyclopropyl-isoxazole-4-carboxylic acid (8-methoxy-5-phenyl-quinoxalin-2-yl)-amide
80	5-Methyl-isoxazole-4-carboxylic acid (8-methoxy-5-phenyl-quinoxalin-2-yl)-amide
81	1-Methyl-1H-pyrazole-4-carboxylic acid (8-methoxy-5-phenyl-quinoxalin-2-yl)-amide
82	6-Oxo-1,6-dihydro-pyridazine-4-carboxylic acid (8-methoxy-5-phenyl-quinoxalin-2-yl)-amide
83	4-Hydroxy-4-methyl-piperidine-1-carboxylic acid (5-butyl-8-methoxy-quinoxalin-2-yl)-amide
84	4-Hydroxy-4-methyl-piperidine-1-carboxylic acid [8-methoxy-5-(1-propyl-cyclopropyl)-quinoxalin-2-yl]-amide
85	4-Hydroxy-4-methyl-piperidine-1-carboxylic acid [8-methoxy-5-(1-methoxymethyl-cyclopropyl)-quinoxalin-2-yl]-amide
86	4-Hydroxy-4-methyl-piperidine-1-carboxylic acid [5-(3-amino-phenyl)-8-methoxy-quinoxalin-2-yl]-amide
87	4-Hydroxy-4-methyl-piperidine-1-carboxylic acid (8-methoxy-5-pyridin-2-yl-quinoxalin-2-yl)-amide
88	4-Hydroxy-4-methyl-piperidine-1-carboxylic acid (8-methoxy-5-o-tolyl-quinoxalin-2-yl)-amide
89	1-Cyano-cyclopropanecarboxylic acid (5-methoxy-8-phenyl-pyrido[3,4-b]pyrazin-3-yl)-amide
90	Cyclopropanecarboxylic acid (5-methoxy-8-phenyl-pyrido[3,4-b]pyrazin-3-yl)-amide

91	N-[8-methoxy-5-(oxan-4-yl)quinoxalin-2-yl]-2-oxa-7-azaspiro[4.4]nonane-7-carboxamide
92	4-hydroxy-N-[8-methoxy-5-(pyridin-4-yl)quinoxalin-2-yl]-4-methylpiperidine-1-carboxamide
93	3-hydroxy-N-[8-methoxy-5-(oxan-4-yl)quinoxalin-2-yl]-3-methylpyrrolidine-1-carboxamide
94	N-[8-methoxy-5-(oxan-4-yl)quinoxalin-2-yl]-2-methyl-1,3-oxazole-4-carboxamide
95	4-(hydroxymethyl)-N-[8-methoxy-5-(oxan-4-yl)quinoxalin-2-yl]-4-methylpiperidine-1-carboxamide
96	N-[8-methoxy-5-(oxan-4-yl)quinoxalin-2-yl]-2,2-dioxo-2lambda6-thia-6-azaspiro[3.3]heptane-6-carboxamide
97	6-methoxy-N-[8-methoxy-5-(oxan-4-yl)quinoxalin-2-yl]pyridazine-3-carboxamide
98	N-[8-methoxy-5-(oxan-4-yl)quinoxalin-2-yl]-1-(2-methoxyethyl)-1H-pyrazole-4-carboxamide
99	4-hydroxy-N-(8-methoxy-5-phenylquinoxalin-2-yl)-4-(prop-2-yn-1-yl)piperidine-1-carboxamide
100	3-hydroxy-N-(8-methoxy-5-phenylquinoxalin-2-yl)-3-methylpyrrolidine-1-carboxamide
101	4-(hydroxymethyl)-N-(8-methoxy-5-phenylquinoxalin-2-yl)-4-methylpiperidine-1-carboxamide
102	N-(8-methoxy-5-phenylquinoxalin-2-yl)-8-oxa-2-azaspiro[4.5]decane-2-carboxamide

103	4-Hydroxy-4-prop-2-ynyl-piperidine-1-carboxylic acid [5-methoxy-8-(tetrahydro-pyran-4-yl)-pyrido[3,4-b]pyrazin-3-yl]-amide
104	4-Hydroxymethyl-4-methyl-piperidine-1-carboxylic acid [5-methoxy-8-(tetrahydro-pyran-4-yl)-pyrido[3,4-b]pyrazin-3-yl]-amide
105	N-(8-methoxy-5-phenylquinoxalin-2-yl)-2-methyl-1,3-oxazole-5-carboxamide
106	Cyclopropanecarboxylic acid [5-methoxy-8-(tetrahydro-pyran-4-yl)-pyrido[3,4-b]pyrazin-3-yl]-amide
107	N-(8-butyl-5-methoxyquinoxalin-2-yl)-4-hydroxy-4-methylpiperidine-1-carboxamide
108	N-(5-butyl-8-methoxyquinoxalin-2-yl)-4-hydroxy-4-methylpiperidine-1-carboxamide
109	N-[5-(3,6-dihydro-2H-pyran-4-yl)-8-methoxyquinoxalin-2-yl]-4-hydroxy-4-methylpiperidine-1-carboxamide
110	N-[8-(3-fluorophenyl)-5-methoxyquinoxalin-2-yl]-4-hydroxy-4-methylpiperidine-1-carboxamide
111	N-[8-(2-fluorophenyl)-5-methoxyquinoxalin-2-yl]-4-hydroxy-4-methylpiperidine-1-carboxamide
112	4-hydroxy-N-[5-methoxy-8-(pyridin-3-yl)quinoxalin-2-yl]-4-methylpiperidine-1-carboxamide
113	6-methoxy-N-(8-methoxy-5-phenylquinoxalin-2-yl)pyridazine-3-carboxamide

114	4-hydroxy-N-(8-methoxy-5-{1-[(pyridin-2-yl)methyl]-1H-pyrazol-4-yl}quinoxalin-2-yl)-4-methylpiperidine-1-carboxamide
115	4-{2-[(4-hydroxy-4-methylpiperidine-1-carbonyl)amino]-8-methoxyquinoxalin-5-yl}-N-methylpyridine-2-carboxamide
116	tert-butyl 3-(4-{2-[(4-hydroxy-4-methylpiperidine-1-carbonyl)amino]-8-methoxyquinoxalin-5-yl}-1H-pyrazol-1-yl)azetidine-1-carboxylate
117	4-hydroxy-N-{8-methoxy-5-[3-(2-methoxyethoxy)phenyl]quinoxalin-2-yl}-4-methylpiperidine-1-carboxamide
118	4-hydroxy-N-(8-methoxy-5-{3-[(2-methoxyethoxy)methyl]phenyl}quinoxalin-2-yl)-4-methylpiperidine-1-carboxamide
119	4-hydroxy-N-(8-methoxy-5-{1-[2-(2-methoxyethoxy)ethyl]-1H-pyrazol-4-yl}quinoxalin-2-yl)-4-methylpiperidine-1-carboxamide
120	N-[5-(2-fluorophenyl)-8-methoxyquinoxalin-2-yl]cyclopropanecarboxamide
121	N-[8-methoxy-5-(pyridin-3-yl)quinoxalin-2-yl]cyclopropanecarboxamide
122	N-[5-(azepan-1-yl)-8-methoxyquinoxalin-2-yl]cyclopropanecarboxamide
123	N-[5-(2,3-difluorophenyl)-8-methoxyquinoxalin-2-yl]cyclopropanecarboxamide
124	N-[5-(2,5-difluorophenyl)-8-methoxyquinoxalin-2-yl]cyclopropanecarboxamide

125	N-[5-(2,3-difluorophenyl)-8-methoxyquinoxalin-2-yl]-2-methyl-1,3-oxazole-5-carboxamide
126	N-[5-(4-fluorophenyl)-8-methoxyquinoxalin-2-yl]cyclopropanecarboxamide
127	N-[8-methoxy-5-(1,2,3,6-tetrahydropyridin-4-yl)quinoxalin-2-yl]cyclopropanecarboxamide
128	N-[5-(2,5-difluorophenyl)-8-methoxyquinoxalin-2-yl]-2-methyl-1,3-oxazole-5-carboxamide
129	N-[5-(2-fluorophenyl)-8-methoxyquinoxalin-2-yl]-2-methyl-1,3-oxazole-5-carboxamide
130	N-[8-methoxy-5-(oxan-4-yl)quinoxalin-2-yl]-2-methyl-1,3-oxazole-5-carboxamide
131	N-[5-(4-fluorophenyl)-8-methoxyquinoxalin-2-yl]-2-methyl-1,3-oxazole-5-carboxamide
132	N-[5-(3,6-dihydro-2H-pyran-4-yl)-8-methoxyquinoxalin-2-yl]-2-methyl-1,3-oxazole-5-carboxamide
133	N-{5-[1-(azetidin-3-yl)-1H-pyrazol-4-yl]-8-methoxyquinoxalin-2-yl}-4-hydroxy-4-methylpiperidine-1-carboxamide
134	N-[5-(3,6-dihydro-2H-pyran-4-yl)-8-methoxyquinoxalin-2-yl]-2-methyl-1,3-thiazole-5-carboxamide
135	N-[5-(3,6-dihydro-2H-pyran-4-yl)-8-methoxyquinoxalin-2-yl]-1-methyl-1H-pyrazole-4-carboxamide

136	N-[5-(3,6-dihydro-2H-pyran-4-yl)-8-methoxyquinoxalin-2-yl]-1,2-thiazole-4-carboxamide
137	1-amino-N-[5-(3,6-dihydro-2H-pyran-4-yl)-8-methoxyquinoxalin-2-yl]cyclopropane-1-carboxamide
138	N-[8-methoxy-5-(pyridin-3-yl)quinoxalin-2-yl]-2-methyl-1,3-oxazole-5-carboxamide
139	2-amino-N-[5-(3,6-dihydro-2H-pyran-4-yl)-8-methoxyquinoxalin-2-yl]-1,3-thiazole-4-carboxamide
140	N-[5-(3,6-dihydro-2H-pyran-4-yl)-8-methoxyquinoxalin-2-yl]-5-(oxolan-3-yl)-1,3-thiazole-2-carboxamide
141	N-[5-(2,5-dihydrofuran-3-yl)-8-methoxyquinoxalin-2-yl]cyclopropanecarboxamide
142	5-(aminomethyl)-N-[5-(3,6-dihydro-2H-pyran-4-yl)-8-methoxyquinoxalin-2-yl]furan-3-carboxamide
143	ethyl 5-({[5-(3,6-dihydro-2H-pyran-4-yl)-8-methoxyquinoxalin-2-yl]carbamoyl}amino)-1,3,4-thiadiazole-2-carboxylate
144	N'1-[5-(3,6-dihydro-2H-pyran-4-yl)-8-methoxyquinoxalin-2-yl]-N1,N1-dimethylcyclopropane-1,1-dicarboxamide
145	N-[5-(3,6-dihydro-2H-pyran-4-yl)-8-methoxyquinoxalin-2-yl]-1-[(dimethylamino)methyl]cyclopropane-1-carboxamide
146	N-[5-(3,6-dihydro-2H-pyran-4-yl)-8-methoxyquinoxalin-2-yl]-5-methyl-1,3,4-thiadiazole-2-carboxamide

147	N-{8-methoxy-5-[3-(2-methoxyethoxy)phenyl]quinoxalin-2-yl}cyclopropanecarboxamide
148	N-{8-methoxy-5-[3-(2-methoxyethoxy)phenyl]quinoxalin-2-yl}-2-methyl-1,3-oxazole-5-carboxamide
149	N'1-(8-methoxy-5-phenylquinoxalin-2-yl)-N1,N1-dimethylcyclopropane-1,1-dicarboxamide
150	1-[(dimethylamino)methyl]-N-(8-methoxy-5-phenylquinoxalin-2-yl)cyclopropane-1-carboxamide
151	N-{8-methoxy-5-[3-(2-methoxyethoxy)phenyl]quinoxalin-2-yl}-2-methyl-1,3-thiazole-5-carboxamide
152	N-{8-methoxy-5-[3-(2-methoxyethoxy)phenyl]quinoxalin-2-yl}-5-methyl-1,3,4-thiadiazole-2-carboxamide
153	4-hydroxy-N-{8-methoxy-5-[1-(pyridin-2-yl)-1H-pyrazol-4-yl]quinoxalin-2-yl}-4-methylpiperidine-1-carboxamide
154	N-[8-methoxy-5-(6-methylpyridazin-3-yl)quinoxalin-2-yl]-2-methyl-1,3-oxazole-5-carboxamide
155	N-[8-methoxy-5-(2-methoxypyrimidin-5-yl)quinoxalin-2-yl]-2-methyl-1,3-oxazole-5-carboxamide
156	N-[8-methoxy-5-(2-methoxypyrimidin-5-yl)quinoxalin-2-yl]cyclopropanecarboxamide
157	N-{5-[1-(difluoromethyl)-1H-pyrazol-4-yl]-8-methoxyquinoxalin-2-yl}-2-methyl-1,3-oxazole-5-carboxamide

158	N-{5-[1-(difluoromethyl)-1H-pyrazol-4-yl]-8-methoxyquinoxalin-2-yl}-4-hydroxy-4-methylpiperidine-1-carboxamide
159	N-[5-(3,6-dihydro-2H-pyran-4-yl)-8-methoxyquinoxalin-2-yl]-1H-imidazole-5-carboxamide
160	N-(8-methoxy-5-phenylquinoxalin-2-yl)-1H-imidazole-5-carboxamide
161	N-[8-methoxy-5-(1,4-oxazepan-4-yl)quinoxalin-2-yl]cyclopropanecarboxamide

or a physiologically acceptable salt, derivative, solvate, prodrug or stereoisomer thereof.

8. A process for the preparation of a compound of the formula I, comprising



II III IV V

VI VII VIII I

a) a compound of the formula II undergoes a nitration reaction, followed by a reduction to give a compound of formula IV, a compound of formula IV is cyclized to give a compound of formula V, a compound of formula V is chlorinated followed by a copper catalyzed amination reaction to give compound VII, a compound of formula VII is reacted in a Suzuki type reaction to a compound of formula VIII by a catalyst and base, a compound of formula VIII is converted to a compound of formula I by

amidation or carbamide formation conditions wherein Q, Y, R^1, R^2 and R^3 have the meanings as disclosed above,



b) a compound of the formula III is reacted with a boronic ester or acid under Suzuki-type reaction conditions to give a compound of formula IX or reacted with an amine in a nuclophilic substitution reaction under increased temperature to form a compound of formula IX , a compound of formula IX is reduced to a compound of formula X and cyclized to a compound of formula XI , a compound of formula XI is chlorinated followed by copper catalyzed amination to give compound VIII and finally compound VIII is reacted to a compound of formula I under amidation or carbamide formation conditions and wherein Q, Y, R^1, R^2 and R^3 have the meanings as disclosed above,



c) a compound of the formula XIII is reacted with a boronic ester or acid under Suzuki-type reaction conditions to give a compound of formula XIV, a compound of formula XIV is reduced to a compound of formula X and cyclized to a compound of formula XI , a compound of formula XI is tosylated followed by metal catalyzed amination to give compound VIII and finally compound VIII is reacted to a compound of the formula I under amidation or carbamide formation conditions and wherein Q, Y, R^1, R^2 and R^3 have the meanings as disclosed above,

d) a base of a compound of formula I is converted into one of its salts by treatment with an acid, or

e) an acid of a compound of formula I is converted into one of its salts by treatment with a base.

9. A method for inhibiting an adenosine A_{2A} and/or A_{2B} receptor, comprising administering to said receptor a compound of claim 1 or a physiologically acceptable salt, derivative, solvate, prodrug or stereoisomer thereof.

10. A pharmaceutical composition comprising at least one compound according to claim 1 and/or a physiologically acceptable salt, derivative, solvate, prodrug or stereoisomer thereof and at least one excipient and/or adjuvant.

11. The pharmaceutical composition according to claim 10, further comprising at least one further pharmaceutically active compound.

12. A process for the preparation of a pharmaceutical composition according to claim 10, comprising bringing a compound of formula I and/or one of its physiologically acceptable salts, derivatives, solvates, prodrugs or stereoisomers thereof into a dosage form together with a solid, liquid or semi-liquid excipient or adjuvant.

13. Use of an effective amount of a pharmaceutical composition according to claim 10 in the manufacture of a medicament for the treatment and/or prophylaxis of a physiological and/or pathophysiological state, wherein said medicament is to be administered to a subject in need thereof, and wherein an adenosine A_{2A} and/or A_{2B} receptor is inhibited.

14. Use of an effective amount of a pharmaceutical composition according to claim 10 in the manufacture of a medicament for the treatment and/or prophylaxis of a hyperproliferative or infectious disease or disorder, wherein said medicament is to be administered to a subject in need thereof, and wherein an adenosine A_{2A} and/or A_{2B} receptor is inhibited.

15. The use according to Claim 14, wherein the hyperproliferative disease or disorder is cancer.

16. The use according to Claim 15, wherein the cancer is selected from the group consisting of acute lymphocytic leukemia, chronic lymphocytic leukemia, acute granulocytic leukemia, adrenal cortex cancer, bladder cancer, brain cancer, breast cancer, cervical cancer, cervical hyperplasia, cervical cancer, chorio cancer, chronic granulocytic leukemia, chronic lymphocytic leukemia, colon cancer, endometrial cancer, esophageal cancer, essential thrombocytosis, genitourinary carcinoma, glioma, glioblastoma, hairy cell leukemia, head and neck carcinoma, Hodgkin's disease, Kaposi's sarcoma, lung carcinoma, lymphoma, malignant carcinoid carcinoma, malignant hypercalcemia, malignant melanoma, malignant pancreatic insulinoma, medullary thyroid carcinoma, melanoma, multiple myeloma, mycosis fungoides, myeloid leukemia, lymphocytic leukemia, neuroblastoma, non-Hodgkin's lymphoma, non-small cell lung cancer, osteogenic sarcoma, ovarian carcinoma, pancreatic carcinoma, polycythemia vera, primary brain carcinoma, primary macroglobulinemia, prostatic cancer, renal cell cancer, rhabdomyosarcoma, skin cancer, small-cell lung cancer, soft-tissue sarcoma, squamous cell cancer, stomach cancer, testicular cancer, thyroid cancer and Wilms' tumor.

17. The use according to Claim 14, wherein the hyperproliferative disease or disorder is selected from the group consisting of age-related macular degeneration, Crohn's disease, cirrhosis, chronic inflammatory-related disorders, proliferative diabetic retinopathy, proliferative vitreoretinopathy, retinopathy of prematurity, granulomatosis, immune hyperproliferation associated with organ transplantation, immune hyperproliferation associated with tissue transplantation, an immunoproliferative disease, an

immunoproliferative disorder, inflammatory bowel disease, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, vascular hyperproliferation secondary to retinal hypoxia and vasculitis.

18. The use according to Claim 14, wherein the infectious disease or disorder is selected from the group consisting of

a) virally induced infectious diseases which are caused by retroviruses, hepadnaviruses, herpesviruses, flaviviridae and/or adenoviruses wherein the retroviruses are selected from the group consisting of lentiviruses and oncoretroviruses, wherein the lentivirus is selected from the group consisting of HIV-1, HIV-2, FIV, BIV, SIVs, SHIV, CAEV, VMV and EIAV and the oncoretrovirus is selected from the group consisting of HTLV-I, HTLV-II and BLV, the hepadnavirus is selected from the group consisting of HBV, GSHV and WHV, the herpesivirus is selected from the group consisting of HSV I, HSV II, EBV, VZV, HCMV and HHV 8 and the flaviviridae is selected from the group consisting of HCV, West nile and Yellow Fever,

b) bacterial infectious diseases which are caused by Gram-positive bacteria wherein the Gram-positive bacteria are selected from the group consisting of methicillin-susceptible staphylococci, methicillin-resistant staphylococci, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus saprophyticus, coagulase-negative staphylococci, glycopeptides-intermediate susceptible Staphylococcus aureus, penicillin-susceptible streptococci, penicillin-resistant streptococci Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus avium, Streptococcus bovis, Streptococcus lactis, Streptococcus sanguis, Streptococci Group C, Streptococci Group G, viridans streptococci, enterococci,vancomycinsusceptible strains, vancomycin-resistant strains, Enterococcus faecalis, Enterococcus faecium, Clostridium difficile, Iisteria monocytogenes, Corynebacterium jeikeium, Chlamydia spp, C. pneumoniae and Mycobacterium tuberculosis,

c) bacterial infectious diseases which are caused by Gram-negative bacteria wherein the Gram-negative bacteria are selected from the group consisting of the Genus Enterobacteriacae, Escherichia spp., Escherichia

coli, Klebsiella spp., Enterobacter spp., Citrobacter spp., Serratia spp., Proteus spp., Providencia spp., Salmonella spp., Shigella spp., the genus Pseudomonas, P. aeruginosa, Moraxella spp., M. catarrhalis, Haemophilus spp. and Neisseria spp.,

d) infectious diseases induced by intracellular active parasites selected from the group consisting of phylum Apicomplexa, Sarcomastigophora, Trypanosoma, Plasmodia, Leishmania, Babesia or Theileria, Cryptosporidia, Sacrocystida, Amoebia, Coccidia and Trichomonadia.

19. A kit comprising separate packs of

a) a compound according claim 1 or a physiologically acceptable salt, derivative, solvate, prodrug and stereoisomer thereof, and

b) a further pharmaceutically active compound.

20. The compound according to claim 1 or a pharmaceutically acceptable salt thereof.

21. The compound according to claim 7 or a pharmaceutically acceptable salt thereof.